[CAS NO. 1037210-93-7] Saridegib

Ships within

Stock

Price

Qty

Total

COA

Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.

Catalog:	HY-16587
Brand:	MCE
CAS:	1037210-93-7

Overview

MDL	-
Molecular Weight	504.77
Molecular Formula	C29H48N2O3S
SMILES	CC1=C(C[C@@]2([H])[C@@]3([H])CC[C@@]4([H])[C@]2(C)CC[C@@H](NS(C)(=O)=O)C4)[C@@]3([H])CC[C@@]([C@@H]5C)(C1)O[C@@]6([H])[C@@]5([H])NC[C@@H](C)C6

For research use only. We do not sell to patients.

Summary

Saridegib is a potent and specific inhibitor of Smoothened (Smo) , a key signaling transmembrane protein in the Hedgehog (Hh) pathway.

IC50 & Target

Smo ^[1] .

In Vivo

Evidence from a genetically engineered mouse model of pancreatic cancer demonstrates that Saridegib (IPI-926) can deplete tumor-associated stromal tissue and increase intratumoral mean vessel density. These changes result in enhanced delivery of concurrently administered systemic agents, leading to a decreased tumor burden and prolonged survival in this mouse model ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT01310816	Infinity Pharmaceuticals, Inc.	Conventional Chondrosarcoma	February 2011	Phase 2
NCT01609179	Infinity Pharmaceuticals, Inc.	Basal Cell Carcinoma\|Chondrosarcoma	March 2012	Not Applicable
NCT02762084	PellePharm, Inc.	Basal Cell Nevus Syndrome	June 6, 2016	Phase 2
NCT02828111	PellePharm, Inc.	Basal Cell Carcinomas	November 11, 2016	Phase 2
NCT01383538	Andrew Ko\|Infinity Pharmaceuticals, Inc.\|University of California, San Francisco	Pancreatic Cancer\|Adenocarcinoma\|Pancreatic Neoplasms	August 23, 2011	Phase 1
NCT04155190	PellePharm, Inc.	Recurrent Basal Cell Carcinoma	December 20, 2019	Phase 2
NCT03703310	PellePharm, Inc.	Basal Cell Nevus Syndrome	February 19, 2019	Phase 3
NCT01371617	Infinity Pharmaceuticals, Inc.	Primary Myelofibrosis\|Fibrosis, Bone Marrow	October 2011	Phase 2
NCT04308395	PellePharm, Inc.	Basal Cell Nevus Syndrome	June 3, 2020	Phase 3
NCT01130142	Infinity Pharmaceuticals, Inc.	Metastatic Pancreatic Cancer	April 2010	Phase 1\|Phase 2
NCT01255800	University of Colorado, Denver	Recurrent Head and Neck Cancer	April 2011	Phase 1
NCT00761696	Infinity Pharmaceuticals, Inc.	Neoplasms	September 2008	Phase 1

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

References

[1] Ko AH, et al. A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma. Pancreas. 2016 Mar;45(3):370-5.

Synonyms

Methanesulfonamide, N-[(2S,3R,3′R,3aS,4′aR,6S,6′aR,6′bS,7aR,12′aS,12′bS)-2′,3′,3a,4,4′,4′a,5,5′,6,6′,6′a,6′b,7,7′,7a,8′,10′,12′,12′a,12′b-eicosahydro-3,6,11′,12′b-tetramethylspiro[furo[3,2-b]pyridine-2(3H),9′(1′H)-naphth[2,1-a]azulen]-3′-yl]-

N-[(2S,3R,3′R,3aS,4′aR,6S,6′aR,6′bS,7aR,12′aS,12′bS)-2′,3′,3a,4,4′,4′a,5,5′,6,6′,6′a,6′b,7,7′,7a,8′,10′,12′,12′a,12′b-Eicosahydro-3,6,11′,12′b-tetramethylspiro[furo[3,2-b]pyridine-2(3H),9′(1′H)-naphth[2,1-a]azulen]-3′-yl]methanesulfonamide

IPI 926

FIN 5

IP 9

Patidegib

IP 9 (pharmaceutical)

Request a Quote

Please fill in your details below to request a COA for our product. We will send the COA to the provided email address promptly.

Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.

Information

Shipping
Privacy notice
Terms of Service
About us
Contact us

Customer service

Search
Custom Synthesis

My account

My account
Orders
Addresses
Shopping cart